OncoCyte Corporation [OCX] shares are down more than -13.10% this year and recently increased 0.17% or $0.29 to settle at $1.75. OCX has a short ratio of 2.74. This implies that the market is currently less bullish on the outlook for OCX.
On 14, October 2020, Oncocyte Announces New Prospective Data Demonstrating That Treatment Informed by DetermaRx™ Significantly Improves Lung Cancer Patient Survival. According to news published on Yahoo Finance, Data to be Presented by Dr. Gavitt Woodard of Yale University at the IASLC 2020 North America Conference on Lung Cancer.
Analyst Birdseye View:
The most recent analyst activity for OncoCyte Corporation [AMEX:OCX] stock was on July 01, 2020, when it was Downgrade with a Neutral rating from Piper Sandler. Before that, on July 30, 2020, The Benchmark Company Recapitulated a Speculative buy rating and elevated its amount target to $6. On June 30, 2020, Chardan Capital Markets Downgrade a Neutral rating and boosted its price target on this stock to $2. On June 02, 2020, Needham Initiated a Buy rating and increased its price target to $4. On February 13, 2019, Piper Jaffray Initiated an Overweight rating and increased its price target to $6. On January 29, 2019, Janney Upgrade a Buy rating. On December 19, 2018, Lake Street Resumed a Buy rating.
In the past 52 weeks of trading, this stock has oscillated between a low of $1.15 and a peak of $3.51. Right now, according to Wall Street analyst the average 12-month amount target is $3.10. At the most recent market close, shares of OncoCyte Corporation [AMEX:OCX] were valued at $1.75.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 16.14 and the whole liability to whole assets at 14.89. It shows enduring liability to the whole principal at 12.46 and enduring liability to assets at 0.11 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.4267 points at 1st support level, the second support level is making up to 1.3933. But as of 1st resistance point, this stock is sitting at 1.5067 and at 1.5533 for 2nd resistance point.
OncoCyte Corporation [OCX] reported its earnings at -$0.14 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.1/share signifying the difference of -0.04 and -40.00% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.13 calling estimates for -$0.11/share with the difference of -0.02 depicting the surprise of -18.20%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for OncoCyte Corporation [AMEX:OCX] is 2.70. Likewise, the Quick ratio is also the same, showing Cash ratio at 5.06. Now if looking for a valuation of this stock’s amount to book ratio is 4.16.
The most recent insider trade was by ANDREWS RONALD ASBURY, Chief Executive Officer, and it was the purchase of 40000.0 shares on Aug 03. Levine Mitchell S, the Chief Financial Officer, completed a purchase of 10000.0 shares on Aug 03. On Aug 03, Parker Albert P, Chief Operating Officer, completed a purchase of 5000.0 shares.